Monday, September 04, 2023
Oncorena has made a significant announcement regarding the Phase I/II trial of ONC175 (orellanine) for metastatic renal cancer patients requiring dialysis. On August 8, the first treatment was successfully administered at the Center for Clinical Cancer Studies, Karolinska University Hospital in Stockholm, Sweden, without any complications.
The primary goals of this clinical trial, referred to as Oncorella-1, include assessing the safety, tolerability, pharmacokinetics, and anti-tumor effects of ONC175 in this specific patient group.
Börje Haraldsson, CEO and CSO of Oncorena AB, expressed his satisfaction with this pivotal development, emphasizing the pressing need for more effective therapies for these patients.
Since eligible patients are dialysis-dependent, the trial is being conducted at the same hospital where hemodialysis is provided. Subsequent patients are scheduled for treatment in the upcoming autumn season. The progress of each patient will be meticulously monitored, with an independent Data Review Committee evaluating the potential for dose escalations four weeks after infusion.
ONC175 is a promising drug candidate with a unique mechanism of action, offering hope to individuals with metastatic renal cancer and dialysis-dependent renal failure. Preclinical studies have indicated ONC175's highly selective organ-targeted chemotherapy and potent anti-tumor effects against metastatic renal cancer.
Dr. Jeffrey Yachnin, responsible for overseeing the study at the Center for Clinical Cancer Studies, Karolinska University Hospital, expressed enthusiasm for the groundbreaking potential of this medicine in advanced kidney cancer treatment and eagerly awaits the study's outcomes.